Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia

Clinical Infectious Diseases

Volumn 42, Issue 8, 2006, Pages 1093-1101

  Fisman, David N ^a,b,d   Abrutyn, Elias ^a,b   Spaude, Kimberly A ^a   Kim, Alex ^c   Kirchner, Cheryl ^c   Daley, Jennifer ^c  

^a DREXEL UNIVERSITY   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c Princeton University ^*  (United States)

^d PRINCETON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

ADULT; AGED; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; FEMALE; HEALTH CARE QUALITY; HOSPITALIZATION; HUMAN; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RESPIRATORY FAILURE; RISK ASSESSMENT; SMOKING; UNITED STATES; VACCINATION;

ADULT; BACTEREMIA; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; INPATIENTS; LENGTH OF STAY; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; TREATMENT OUTCOME;

EID: 33645773652     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/501354     Document Type: Article

References (56)

1. Robinson KA, Baughman W, Rothrock G, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA 2001; 285:1729-35.
2. Greenwood B. The epidemiology of pneumococcal infection in children in the developing world. Philos Trans R Soc Lond B Biol Sci 1999; 354:777-85.
3. Mulholland K. Global burden of acute respiratory infections in children: implications for interventions. Pediatr Pulmonol 2003; 36:469-74.
4. Adam D. Global antibiotic resistance in Streptococcus pneumoniae. J Antimicrob Chemother 2002; 50(Suppl 1):1-5.
5. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37:1405-33.
6. Laupland KB, Davies HD, Kellner JD, et al. Predictors and outcome of admission for invasive Streptococcus pneumoniae infections at a Canadian children's hospital. Clin Infect Dis 1998; 27:597-602.
7. Kyaw MH, Christie P, Clarke SC, et al. Invasive pneumococcal disease in Scotland, 1999-2001: use of record linkage to explore associations between patients and disease in relation to future vaccination policy. Clin Infect Dis 2003; 37:1283-91.
8. Esposito AL. Community-acquired bacteremic pneumococcal pneumonia: effect of age on manifestations and outcome. Arch Intern Med 1984; 144:945-8.
9. Kupronis BA, Richards CL, Whitney CG. Invasive pneumococcal disease in older adults residing in long-term care facilities and in the community. J Am Geriatr Soc 2003; 51:1520-5.
10. Austrian R, Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964; 60:759-76.
11. Hook EW III, Horton CA, Schaberg DR. Failure of intensive care unit support to influence mortality from pneumococcal bacteremia. JAMA 1983; 249:1055-7.
12. Whitney CG, Parley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343:1917-24.
13. Dagan R. The potential of pneumococcal conjugate vaccines to reduce antibiotic resistance. Adv Exp Med Biol 2004; 549:211-9.
14. Centers for Disease Control and Prevention. Recommended adult immunization schedule-United States, October 2005-September 2006. MMWR Morb Mortal Wkly Rep 2005; 54:Q1-4.
15. CDC National Immunization Program. Adult immunization schedule. Available at: http://www.cdc.gov/nip/recs/adult-schedule.htm. Accessed 10 March 2006.
16. Koivula I, Sten M, Leinonen M, Makela PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med 1997; 103:281-90.
17. Cornu C, Yzebe D, Leophonte P, Gaillat J, Boissel JP, Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine 2001; 19:4780-90.
18. Simberkoff MS, Cross AP, Al Ibrahim M, et al. Efficacy of pneumococcal vaccine in high-risk patients: results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 315:1318-27.
19. Smit P, Oberholzer D, Hayden-Smith S, Koornhof HJ, Hilleman MR. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 1977; 238:2613-6.
20. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325:1453-60.
21. Rubins JB, Janoff EN. Pneumococcal disease in the elderly: what is preventing vaccine efficacy? Drugs Aging 2001; 18:305-11.
22. Riley ID, Douglas RM. An epidemiologic approach to pneumococcal disease. Rev Infect Dis 1981; 3:233-45.
23. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348:1747-55.
24. Christenson B, Lundbergh P, Hedlund J, Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet 2001; 357:1008-11.
25. Hedlund J, Christenson B, Lundbergh P, Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in elderly people: a 1-year follow-up. Vaccine 2003; 21:3906-11.
26. Blais L, Ernst P, Suissa S. Confounding by indication and channeling over time: the risks of beta 2-agonists. Am J Epidemiol 1996; 144:1161-9.
27. Loeb M, Stevenson KB. Pneumococcal immunization in older adults: implications for the long-term-care setting. Infect Control Hosp Epidemiol 2004; 25:985-94.
28. Centers for Disease Control and Prevention. Influenza and pneumococcal vaccination coverage among persons aged ≥65 years and persons aged 18-64 years with diabetes or asthma-United States, 2003. MMWR Morb Mortal Wkly Rep 2004; 53:1007-12
29. (erratum: MMWR Morb Mortal Wkly Rep 2005; 54:935).
30. Tenet HealthSystem Medical. Tenet: our hospitals. Available at: http://www.tenethealth.com/TenetHealth/OurHospitals.Last. Accessed 5 April 2005.
31. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243-50.
32. Bloom HG, Wheeler DA, Linn J. A managed care organization's attempt to increase influenza and pneumococcal immunizations for older adults in an acute care setting. J Am Geriatr Soc 1999; 47:106-10.
33. Armitage P, Berry G, Matthews JNS. Comparison of several groups. In: Armitage P, Berry G, Matthews JNS. Statistical methods in medical research. Oxford, UK: Blackwell Science, 2002:208-35.
34. Klein JP, Moeschberger ML. Censoring and truncating. In: Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. New York: Springer, 1997:55-82.
35. Woodward M. Modelling binary outcome data. In: Woodward M. Epidemiology: study design and data analysis. Boca Raton, FL: Chapman & Hall/CRC, 2005:515-600.
36. Hosmer DW, Lemeshow S. Model-building strategies and methods for logistic regression. In: Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley and Sons, 1989:82-134.
37. Rothman K, Greenland S. Introduction to stratified analysis. In: Rothman K, Greenland S, eds. Modern epidemiology. Philadelphia: Lippincott-Raven, 1998:253-77.
38. Tuomanen EI, Austrian R, Masure HR. Pathogenesis of pneumococcal infection. N Engl J Med 1995; 332:1280-4.
39. Klein JO, Moeschberger ML. Refinements of the semiparametric proportional hazards model. In: Survival analysis: techniques for censored and truncated data. New York: Springer, 1997:269-303.
40. Greenland S, Rothman KJ. Fundamentals of epidemiologic data analysis. In: Rothman KJ, Greenland S, eds. Modern epidemiology. Philadelphia: Lippincott-Raven, 1998:201-30.
41. Dowell SF, Whitney CG, Wright C, Rose CE Jr, Schuchat A. Seasonal patterns of invasive pneumococcal disease. Emerg Infect Dis 2003; 9:573-9.
42. Jensen ES, Lundbye-Christensen S, Pedersen L, Sorensen HT, Schonheyder HC. Seasonal variation in meningococcal disease in Denmark: relation to age and meningococcal phenotype. Scand J Infect Dis 2003; 35:226-9.
43. Mangtani P, Cutts F, Hall AJ. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect Dis 2003; 3:71-8.
44. Wagner C, Popp W, Posch M, Vlasich C, Rosenberger-Spitzy A. Impact of pneumococcal vaccination on morbidity and mortality of geriatric patients: a case-controlled study. Gerontology 2003; 49:246-50.
45. Finland M. Pneumonia and pneumococcal infections, with special reference to pneumococcal pneumonia. The 1979 J. Burns Amberson lecture. Am Rev Respir Dis 1979; 120:481-502.
46. Valles J, Rello J, Ochagavia A, Garnacho J, Alcala MA. Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest 2003; 123:1615-24.
47. Lippmann ML, Goldberg SK, Walkenstein MD, Herring W, Gordon M. Bacteremic pneumococcal pneumonia: a community hospital experience. Chest 1995; 108:1608-13.
48. Metlay JP, Hofmann J, Cetron MS, et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000; 30:520-8.
49. Clemens JD, Shapiro ED. Resolving the pneumococcal vaccine controversy: are there alternatives to randomized clinical trials? Rev Infect Dis 1984; 6:589-600.
50. Aujesky D, Auble TE, Yealy DM, et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med 2005; 118:384-92.
51. Mangtani P, Roberts JA, Hall AJ, Cutts FT. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting. Int J Epidemiol 2005; 34:565-74.
52. Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med 2003; 138:960-8.
53. Centers for Medicare and Medicaid Services. Medicare provider analysis and review. Baltimore: US Department of Health and Human Services, 2006. Available at: http://www.cms.hhs.gov/Medicare-FeeforSvcPartsAB/03_MEDPAR.asp. Accessed 10 March 2006.
54. Hutchison BG, Oxman AD, Shannon HS, Lloyd S, Altmayer CA, Thomas K. Clinical effectiveness of pneumococcal vaccine: meta-analysis. Can Fam Physician 1999; 45:2381-93.
55. Poolman JT. Pneumococcal vaccine development. Expert Rev Vaccines 2004; 3:597-604.
56. Willis BC, Ndiaye SM, Hopkins DP, Shefer A. Improving influenza, pneumococcal polysaccharide, and hepatitis B vaccination coverage among adults aged <65 years at high risk: a report on recommendations of the Task Force on Community Preventive Services. MMWR Recomm Rep 2005; 54:1-11.